Evidence map›Paper›PMID 34895748›Full record

ArticleMedicina clinica2022

Analysis of cardiovascular disease factors on SARS-CoV-2 infection severity.

Zai-Qiang Zhang, Jian-Qiao Wan, Sheng-Kui Zhu, Man Wang, Xin-An Wang, Xiao-Hong Tong, Jia-Wang Ding

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina clinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zai-Qiang ZhangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, Hubei Province, China.
Jian-Qiao WanDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, Hubei Province, China.
Sheng-Kui ZhuDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, Hubei Province, China.
Man WangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, Hubei Province, China.
Xin-An WangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, Hubei Province, China.
Xiao-Hong TongDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, Hubei Province, China.
Jia-Wang DingDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang, Hubei Province, China. Electronic address: dingjiawang@163.com.
China Three Gorges University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt present, COVID-19 is a global pandemic and is seriously harmful to humans. In this retrospective study, the aim was to investigate the interaction between CVD and COVID-19.

methodsA total of 180 patients diagnosed with COVID-19 in Yichang Central People's Hospital from 29 January to 17 March 2020 were initially included. The medical history, clinical manifestations at the time of admission, laboratory test results, hospitalization time and complications were recorded. According to the medical history, the patients were assigned to the nonsevere group with non-CVD (n=90), the nonsevere group with CVD (n=22), the severe group with non-CVD (n=40) and the severe group with CVD (n=28).

resultsIn the severe group, compared with non-CVD patients, CVD patients had a significantly higher incidence of fever (P<0.05). However, compared with the nonsevere group, the severe group had significantly higher proportions of patients with hypertension, type 2 diabetes mellitus, CHD and HF (all P<0.05). Among the patients with nonsevere COVID-19, the WBC count and the levels of IL-6, CRP, D-dimer, NT-proBNP, and FBG were significantly higher and the Hb level was significantly lower in the CVD patients than in the non-CVD patients (all P<0.05). However, among the patients with severe COVID-19, only the level of NT-proBNP was significantly higher in CVD patients than in non-CVD patients (P<0.05). In addition, the WBC count and the levels of IL-6, CRP, D-dimer, CKMB, ALT, AST, SCR, NT-proBNP, and FBG were significantly higher and the Hb level was significantly lower in the severe group than in the nonsevere group (all P<0.05). However, among the patients with severe COVID-19, the incidences of acute myocardial injury, acute kidney injury, arrhythmia, and sudden death were significantly higher in the CVD group than in the non-CVD group (all P<0.05). The same results were found in the comparison of the nonsevere group with the severe group. Among the patients with nonsevere COVID-19, those without CVD had a mean hospitalization duration of 25.25 (SD 7.61) days, while those with CVD had a mean hospitalization duration of 28.77 (SD 6.11) days; the difference was significant (P<0.05). The same results were found in the comparison of the severe group.

conclusionsCVD affects the severity of COVID-19. COVID-19 also increases the risk of severe CVD.

Indexed as

Cardiovascular DiseasesCOVID-19Diabetes Mellitus, Type 2HumansInterleukin-6Retrospective StudiesSARS-CoV-2Interleukin-6Cardiovascular disease (CVD)Complicaciones clínicas gravesCoronavirus disease 2019 (COVID-19)Enfermedad del coronavirus en 2019 (COVID-19)Enfermedades cardiovascularesLesión miocárdicaMyocardial injurySevere clinical complications

Identifiers

PMID34895748
PMCPMC8563366
OpenAlexW3208314355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.